{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:20:01Z","timestamp":1794918001110,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As a first-line treatment, radiotherapy (RT) is known to modulate the immune microenvironment of glioma, but it is unknown whether the meningeal lymphatic vessel (MLV)-cervical lymph node (CLN) network regulates the process or influences RT efficacy. Here, we show that the MLV-CLN network contributes to RT efficacy in brain tumors and mediates the RT-modulated anti-tumor immunity that is enhanced by vascular endothelial growth factor C (VEGF-C). Meningeal lymphatic dysfunction impaired tumor-derived dendritic cell (DC) trafficking and CD8<jats:sup>+<\/jats:sup> T cell activation after RT, whereas tumors overexpressing VEGF-C with meningeal lymphatic expansion were highly sensitive to RT. Mechanistically, VEGF-C-driven modulation of RT-triggered anti-tumor immunity was attributed to C-C Motif Chemokine Ligand 21 (CCL21)-dependent DC trafficking and CD8<jats:sup>+<\/jats:sup> T cell activation. Notably, delivery of VEGF-C mRNA significantly enhanced RT efficacy and anti-tumor immunity in brain tumors. These findings suggest an essential role of the MLV-CLN network in RT-triggered anti-tumor immunity, and highlight the potential of VEGF-C mRNA for brain tumor therapy.<\/jats:p>","DOI":"10.1038\/s41422-022-00639-5","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T08:05:19Z","timestamp":1647504319000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity"],"prefix":"10.1038","volume":"32","author":[{"given":"Changping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-8776","authenticated-orcid":false,"given":"Jincai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"639_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41582-019-0178-0","volume":"15","author":"AS Berghoff","year":"2019","unstructured":"Berghoff, A. S. & Preusser, M. Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome? Nat. Rev. Neurol. 15, 314\u2013315 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"639_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/PPO.0000000000000237","volume":"23","author":"I Glitza Oliva","year":"2017","unstructured":"Glitza Oliva, I., Tawbi, H. & Davies, M. A. Melanoma brain metastases: current areas of investigation and future directions. Cancer J. 23, 68\u201374 (2017).","journal-title":"Cancer J."},{"key":"639_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson, J. H., Gunn, M. D., Fecci, P. E. & Ashley, D. M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 20, 12\u201325 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"639_CR4","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-20-1135","volume":"26","author":"M Khasraw","year":"2020","unstructured":"Khasraw, M., Reardon, D. A., Weller, M. & Sampson, J. H. PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin. Cancer Res. 26, 5287\u20135296 (2020).","journal-title":"Clin. Cancer Res."},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"639_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40478-018-0621-2","volume":"6","author":"F Erhart","year":"2018","unstructured":"Erhart, F. et al. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathol. Commun. 6, 135 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"639_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"639_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470\u2013476 (2019).","journal-title":"Nat. Med."},{"key":"639_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"639_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2603","volume":"9","author":"KM Prise","year":"2009","unstructured":"Prise, K. M. & O\u2019Sullivan, J. M. Radiation-induced bystander signalling in cancer therapy. Nat. Rev. Cancer 9, 351\u2013360 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"639_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin, D. E. Recent developments in radiotherapy. N. Engl. J. Med. 377, 1065\u20131075 (2017).","journal-title":"N. Engl. J. Med."},{"key":"639_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2, 286\u2013294 (2016).","journal-title":"Trends Cancer"},{"key":"639_CR13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"639_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","volume":"16","author":"C Grassberger","year":"2019","unstructured":"Grassberger, C., Ellsworth, S. G., Wilks, M. Q., Keane, F. K. & Loeffler, J. S. Assessing the interactions between radiotherapy and antitumour immunity. Nat. Rev. Clin. Oncol. 16, 729\u2013745 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"639_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng, J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343\u2013349 (2013).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"639_CR16","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","volume":"24","author":"E Ladomersky","year":"2018","unstructured":"Ladomersky, E. et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin. Cancer Res. 24, 2559\u20132573 (2018).","journal-title":"Clin. Cancer Res."},{"key":"639_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11060-020-03481-0","volume":"151","author":"HY Chan","year":"2021","unstructured":"Chan, H. Y., Choi, J., Jackson, C. & Lim, M. Combination immunotherapy strategies for glioblastoma. J. Neurooncol. 151, 375\u2013391 (2021).","journal-title":"J. Neurooncol."},{"key":"639_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","volume":"21","author":"A Louveau","year":"2018","unstructured":"Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380\u20131391 (2018).","journal-title":"Nat. Neurosci."},{"key":"639_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41422-020-0287-8","volume":"30","author":"X Hu","year":"2020","unstructured":"Hu, X. et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 30, 229\u2013243 (2020).","journal-title":"Cell Res."},{"key":"639_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41586-018-0368-8","volume":"560","author":"S Da Mesquita","year":"2018","unstructured":"Da Mesquita, S. et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer\u2019s disease. Nature 560, 185\u2013191 (2018).","journal-title":"Nature"},{"key":"639_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita, S. et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature 593, 255\u2013260 (2021).","journal-title":"Nature"},{"key":"639_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","volume":"577","author":"E Song","year":"2020","unstructured":"Song, E. et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577, 689\u2013694 (2020).","journal-title":"Nature"},{"key":"639_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13324-w","volume":"10","author":"E Esposito","year":"2019","unstructured":"Esposito, E. et al. Brain-to-cervical lymph node signaling after stroke. Nat. Commun. 10, 5306 (2019).","journal-title":"Nat. Commun."},{"key":"639_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"639_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"639_CR27","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","volume":"66","author":"PE Fecci","year":"2006","unstructured":"Fecci, P. E. et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294\u20133302 (2006).","journal-title":"Cancer Res."},{"key":"639_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"639_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41586-019-1419-5","volume":"572","author":"JH Ahn","year":"2019","unstructured":"Ahn, J. H. et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature 572, 62\u201366 (2019).","journal-title":"Nature"},{"key":"639_CR30","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1084\/jem.20170391","volume":"214","author":"S Antila","year":"2017","unstructured":"Antila, S. et al. Development and plasticity of meningeal lymphatic vessels. J. Exp. Med. 214, 3645\u20133667 (2017).","journal-title":"J. Exp. Med."},{"key":"639_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"639_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08271-x","volume":"10","author":"J Yan","year":"2019","unstructured":"Yan, J. et al. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat. Commun. 10, 448 (2019).","journal-title":"Nat. Commun."},{"key":"639_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3171\/2016.5.JNS1685","volume":"126","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Putamen involvement and survival outcomes in patients with insular low-grade gliomas. J. Neurosurg. 126, 1788\u20131794 (2017).","journal-title":"J. Neurosurg."},{"key":"639_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.24","volume":"4","author":"Z Zhao","year":"2017","unstructured":"Zhao, Z. et al. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci. Data 4, 170024 (2017).","journal-title":"Sci. Data"},{"key":"639_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1535-6108(02)00051-X","volume":"1","author":"K Alitalo","year":"2002","unstructured":"Alitalo, K. & Carmeliet, P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219\u2013227 (2002).","journal-title":"Cancer Cell"},{"key":"639_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addr.2015.12.011","volume":"99","author":"LC Dieterich","year":"2016","unstructured":"Dieterich, L. C. & Detmar, M. Tumor lymphangiogenesis and new drug development. Adv. Drug Deliv. Rev. 99, 148\u2013160 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"639_CR37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1158\/2326-6066.CIR-19-0828","volume":"8","author":"J Son","year":"2020","unstructured":"Son, J. et al. Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33\/ST2 signaling. Cancer Immunol. Res. 8, 1393\u20131406 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"639_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2007.04.017","volume":"27","author":"T Yamaguchi","year":"2007","unstructured":"Yamaguchi, T. et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27, 145\u2013159 (2007).","journal-title":"Immunity"},{"key":"639_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.celrep.2012.12.013","volume":"3","author":"KM Joo","year":"2013","unstructured":"Joo, K. M. et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3, 260\u2013273 (2013).","journal-title":"Cell Rep."},{"key":"639_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-013-9407-0","volume":"17","author":"LA Johnson","year":"2014","unstructured":"Johnson, L. A. & Jackson, D. G. Control of dendritic cell trafficking in lymphatics by chemokines. Angiogenesis 17, 335\u2013345 (2014).","journal-title":"Angiogenesis"},{"key":"639_CR41","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1093\/emboj\/16.13.3898","volume":"16","author":"V Joukov","year":"1997","unstructured":"Joukov, V. et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898\u20133911 (1997).","journal-title":"EMBO J."},{"key":"639_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0022-1759(92)90092-8","volume":"152","author":"MJ Coloma","year":"1992","unstructured":"Coloma, M. J., Hastings, A., Wims, L. A. & Morrison, S. L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods 152, 89\u2013104 (1992).","journal-title":"J. Immunol. Methods"},{"key":"639_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"639_CR44","doi-asserted-by":"publisher","first-page":"e124507","DOI":"10.1172\/jci.insight.124507","volume":"3","author":"MF Fransen","year":"2018","unstructured":"Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight 3, e124507 (2018).","journal-title":"JCI Insight"},{"key":"639_CR45","doi-asserted-by":"publisher","first-page":"e000867","DOI":"10.1136\/jitc-2020-000867","volume":"8","author":"ZS Buchwald","year":"2020","unstructured":"Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother. Cancer 8, e000867 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"639_CR46","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","volume":"70","author":"T Takeshima","year":"2010","unstructured":"Takeshima, T. et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70, 2697\u20132706 (2010).","journal-title":"Cancer Res."},{"key":"639_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20, 203\u2013217 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"639_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2017","unstructured":"Kim, J. E. et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin. Cancer Res. 23, 124\u2013136 (2017).","journal-title":"Clin. Cancer Res."},{"key":"639_CR49","doi-asserted-by":"publisher","first-page":"671044","DOI":"10.3389\/fonc.2021.671044","volume":"11","author":"M De Martino","year":"2021","unstructured":"De Martino, M. et al. Exploiting radiation therapy to restore immune reactivity of glioblastoma. Front. Oncol. 11, 671044 (2021).","journal-title":"Front. Oncol."},{"key":"639_CR50","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/path.2476","volume":"217","author":"M van Zwam","year":"2009","unstructured":"van Zwam, M. et al. Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis. J. Pathol. 217, 543\u2013551 (2009).","journal-title":"J. Pathol."},{"key":"639_CR51","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.bioactmat.2020.07.003","volume":"5","author":"T Yang","year":"2020","unstructured":"Yang, T. et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact. Mater. 5, 1053\u20131061 (2020).","journal-title":"Bioact. Mater."},{"key":"639_CR52","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1073\/pnas.0913939107","volume":"107","author":"C Wang","year":"2010","unstructured":"Wang, C. et al. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc. Natl. Acad. Sci. USA 107, 1518\u20131523 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00639-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:17:19Z","timestamp":1669303039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00639-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1038\/s41422-022-00639-5","relation":{},"ISSN":["1748-7838"],"issn-type":[{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}